I-Semalutide, i-glucagon efana ne-peptide (GLP-1) i-receptor agonist, ivunyiwe kunyango lwe-2 yeswekile. I-Somaglutide yaphuhliswa nguNovo Nordisk kwi-2012 njengenye indlela yexesha elide kwiLiraglutide. Xa kuthelekiswa neLiraglutide kunye namanye amayeza esifo seswekile, enye yeenzuzo zeSomaglutide kukuba inexesha elide lesenzo, ke kanye ngeveki inaliti yanele. NgoDisemba 2017, i-US Food and Drug Administration (FDA) ivume uhlobo lwenaliti ye-somalutide. Uvavanyo lwekliniki lwangaphambili lwesigaba se-II lufumene ukuba i-Somaglutide yanciphisa ubunzima bohlobo lwe-2 yesifo sikashukela kunye nabantu abatyebileyo, kwaye ukulahlekelwa kwesisindo kwakucatshangelwa ngenxa yokunciphisa amandla okubangelwa kukunciphisa ukutya.